Hodgkin lymphoma
Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma
February 14, 2019Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma
Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …
MSD’s Keytruda notches another FDA approval in Hodgkin lymphoma
March 15, 2017Research and Development, Sales and Marketing Hodgkin lymphoma, MSD, keytruda
MSD, otherwise known as Merck in North America, continues to score indication successes with Keytruda, this time in Hodgkin lymphoma. …
Survivors of Hodgkin lymphoma over twice as likely to suffer second cancer
March 14, 2017Manufacturing and Production, Research and Development Hodgkin lymphoma, ICR
New research emerging from the Institute for Cancer Research (ICR) has found that those previously treated for Hodgkin lymphoma are …
Opdivo nabs FDA approval in specific patients with Hodgkin lymphoma
May 18, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Hodgkin lymphoma, opdivo
Bristol-Myers Squibb (NYSE: BMY) has announced that the US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the …
MSD receives fourth Breakthrough Therapy Designation for Keytruda
April 19, 2016Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …
Takeda reveals five-year Adcetris survival data
December 6, 2015Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology
Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …
